Cargando…

Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach

BACKGROUND: Mesenchymal stromal cells (MSCs), commonly sourced from adipose tissue, bone marrow and umbilical cord, have been widely used in many medical conditions due to their therapeutic potential. Yet, the still limited understanding of the underlying mechanisms of action hampers clinical transl...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcat-i-Cervera, Sandra, Rendra, Erika, Scaccia, Eleonora, Amadeo, Francesco, Hanson, Vivien, Wilm, Bettina, Murray, Patricia, O’Brien, Timothy, Taylor, Arthur, Bieback, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161493/
https://www.ncbi.nlm.nih.gov/pubmed/37143116
http://dx.doi.org/10.1186/s13287-023-03352-1
_version_ 1785037506290384896
author Calcat-i-Cervera, Sandra
Rendra, Erika
Scaccia, Eleonora
Amadeo, Francesco
Hanson, Vivien
Wilm, Bettina
Murray, Patricia
O’Brien, Timothy
Taylor, Arthur
Bieback, Karen
author_facet Calcat-i-Cervera, Sandra
Rendra, Erika
Scaccia, Eleonora
Amadeo, Francesco
Hanson, Vivien
Wilm, Bettina
Murray, Patricia
O’Brien, Timothy
Taylor, Arthur
Bieback, Karen
author_sort Calcat-i-Cervera, Sandra
collection PubMed
description BACKGROUND: Mesenchymal stromal cells (MSCs), commonly sourced from adipose tissue, bone marrow and umbilical cord, have been widely used in many medical conditions due to their therapeutic potential. Yet, the still limited understanding of the underlying mechanisms of action hampers clinical translation. Clinical potency can vary considerably depending on tissue source, donor attributes, but importantly, also culture conditions. Lack of standard procedures hinders inter-study comparability and delays the progression of the field. The aim of this study was A- to assess the impact on MSC characteristics when different laboratories, performed analysis on the same MSC material using harmonised culture conditions and B- to understand source-specific differences. METHODS: Three independent institutions performed a head-to-head comparison of human-derived adipose (A-), bone marrow (BM-), and umbilical cord (UC-) MSCs using harmonised culture conditions. In each centre, cells from one specific tissue source were isolated and later distributed across the network to assess their biological properties, including cell expansion, immune phenotype, and tri-lineage differentiation (part A). To assess tissue-specific function, angiogenic and immunomodulatory properties and the in vivo biodistribution were compared in one expert lab (part B). RESULTS: By implementing a harmonised manufacturing workflow, we obtained largely reproducible results across three independent laboratories in part A of our study. Unique growth patterns and differentiation potential were observed for each tissue source, with similar trends observed between centres. Immune phenotyping verified expression of typical MSC surface markers and absence of contaminating surface markers. Depending on the established protocols in the different laboratories, quantitative data varied slightly. Functional experiments in part B concluded that conditioned media from BM-MSCs significantly enhanced tubulogenesis and endothelial migration in vitro. In contrast, immunomodulatory studies reported superior immunosuppressive abilities for A-MSCs. Biodistribution studies in healthy mice showed lung entrapment after administration of all three types of MSCs, with a significantly faster clearance of BM-MSCs. CONCLUSION: These results show the heterogeneous behaviour and regenerative properties of MSCs as a reflection of intrinsic tissue-origin properties while providing evidence that the use of harmonised culture procedures can reduce but do not eliminate inter-lab and operator differences. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03352-1.
format Online
Article
Text
id pubmed-10161493
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101614932023-05-06 Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach Calcat-i-Cervera, Sandra Rendra, Erika Scaccia, Eleonora Amadeo, Francesco Hanson, Vivien Wilm, Bettina Murray, Patricia O’Brien, Timothy Taylor, Arthur Bieback, Karen Stem Cell Res Ther Research BACKGROUND: Mesenchymal stromal cells (MSCs), commonly sourced from adipose tissue, bone marrow and umbilical cord, have been widely used in many medical conditions due to their therapeutic potential. Yet, the still limited understanding of the underlying mechanisms of action hampers clinical translation. Clinical potency can vary considerably depending on tissue source, donor attributes, but importantly, also culture conditions. Lack of standard procedures hinders inter-study comparability and delays the progression of the field. The aim of this study was A- to assess the impact on MSC characteristics when different laboratories, performed analysis on the same MSC material using harmonised culture conditions and B- to understand source-specific differences. METHODS: Three independent institutions performed a head-to-head comparison of human-derived adipose (A-), bone marrow (BM-), and umbilical cord (UC-) MSCs using harmonised culture conditions. In each centre, cells from one specific tissue source were isolated and later distributed across the network to assess their biological properties, including cell expansion, immune phenotype, and tri-lineage differentiation (part A). To assess tissue-specific function, angiogenic and immunomodulatory properties and the in vivo biodistribution were compared in one expert lab (part B). RESULTS: By implementing a harmonised manufacturing workflow, we obtained largely reproducible results across three independent laboratories in part A of our study. Unique growth patterns and differentiation potential were observed for each tissue source, with similar trends observed between centres. Immune phenotyping verified expression of typical MSC surface markers and absence of contaminating surface markers. Depending on the established protocols in the different laboratories, quantitative data varied slightly. Functional experiments in part B concluded that conditioned media from BM-MSCs significantly enhanced tubulogenesis and endothelial migration in vitro. In contrast, immunomodulatory studies reported superior immunosuppressive abilities for A-MSCs. Biodistribution studies in healthy mice showed lung entrapment after administration of all three types of MSCs, with a significantly faster clearance of BM-MSCs. CONCLUSION: These results show the heterogeneous behaviour and regenerative properties of MSCs as a reflection of intrinsic tissue-origin properties while providing evidence that the use of harmonised culture procedures can reduce but do not eliminate inter-lab and operator differences. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03352-1. BioMed Central 2023-05-04 /pmc/articles/PMC10161493/ /pubmed/37143116 http://dx.doi.org/10.1186/s13287-023-03352-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Calcat-i-Cervera, Sandra
Rendra, Erika
Scaccia, Eleonora
Amadeo, Francesco
Hanson, Vivien
Wilm, Bettina
Murray, Patricia
O’Brien, Timothy
Taylor, Arthur
Bieback, Karen
Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
title Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
title_full Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
title_fullStr Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
title_full_unstemmed Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
title_short Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
title_sort harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161493/
https://www.ncbi.nlm.nih.gov/pubmed/37143116
http://dx.doi.org/10.1186/s13287-023-03352-1
work_keys_str_mv AT calcaticerverasandra harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT rendraerika harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT scacciaeleonora harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT amadeofrancesco harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT hansonvivien harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT wilmbettina harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT murraypatricia harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT obrientimothy harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT taylorarthur harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach
AT biebackkaren harmonisedcultureproceduresminimisebutdonoteliminatemesenchymalstromalcelldonorandtissuevariabilityinadecentralisedmulticentremanufacturingapproach